In an interview with PharmaShots, John Valliant, CEO at Fusion Pharma shared his views on the company's agreement with AstraZeneca, signed in Nov 2020. He also shared in-depth information about the company's TATs platform & Fast-Clear linker technology and provide a glance at Fusion's portfolio.Shots: Fusion to receive $5M up front and $40M as milestones & other payments. The…
